Skip to main content
. Author manuscript; available in PMC: 2020 May 6.
Published in final edited form as: Cancer Discov. 2019 Aug 29;9(11):1538–1555. doi: 10.1158/2159-8290.CD-19-0189

Figure 7 │. THZ1 blocks CRPC growth in vivo.

Figure 7 │

(a) Schematic illustrating the VCaP CRPC mouse xenograft experimental design. (b) Castrated mice bearing VCaP CRPC xenograft received vehicle-D5W (n=8) or 10mg/kg THZ1 (n=8) twice daily for 4 weeks. The percent change in volume for each tumor after 28 days of treatment is shown as a waterfall plot (y axis). (c) Representative images of H&E, p-MED1, PSA, Cl.Caspase3, and KI-67 immunohistochemistry staining of THZ1 or vehicle treated VCaP CRPC xenograft tumors. (d) Plasma PSA levels in vehicle and THZ1 treated mice. P-values were computed using two-tailed student’s t-test. (e) Proposed model of the mechanism of action of CDK7 inhibition in AR-addicted CRPC.

HHS Vulnerability Disclosure